Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models.

Ng SY, Yoshida N, Christie AL, Ghandi M, Dharia NV, Dempster J, Murakami M, Shigemori K, Morrow SN, Van Scoyk A, Cordero NA, Stevenson KE, Puligandla M, Haas B, Lo C, Meyers R, Gao G, Cherniack A, Louissaint A Jr, Nardi V, Thorner AR, Long H, Qiu X, Morgan EA, Dorfman DM, Fiore D, Jang J, Epstein AL, Dogan A, Zhang Y, Horwitz SM, Jacobsen ED, Santiago S, Ren JG, Guerlavais V, Annis DA, Aivado M, Saleh MN, Mehta A, Tsherniak A, Root D, Vazquez F, Hahn WC, Inghirami G, Aster JC, Weinstock DM, Koch R.

Nat Commun. 2018 May 22;9(1):2024. doi: 10.1038/s41467-018-04356-9.

2.

Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia.

Carvajal LA, Neriah DB, Senecal A, Benard L, Thiruthuvanathan V, Yatsenko T, Narayanagari SR, Wheat JC, Todorova TI, Mitchell K, Kenworthy C, Guerlavais V, Annis DA, Bartholdy B, Will B, Anampa JD, Mantzaris I, Aivado M, Singer RH, Coleman RA, Verma A, Steidl U.

Sci Transl Med. 2018 Apr 11;10(436). pii: eaao3003. doi: 10.1126/scitranslmed.aao3003.

3.

Hepatobiliary laboratory abnormalities among patients with chronic or persistent immune thrombocytopenia (ITP).

Enger C, Bennett D, Dawson KL, Aivado MA, Theodore D, McAfee AT.

Ann Hepatol. 2011 Apr-Jun;10(2):188-95.

4.

Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study.

Cheng G, Saleh MN, Marcher C, Vasey S, Mayer B, Aivado M, Arning M, Stone NL, Bussel JB.

Lancet. 2011 Jan 29;377(9763):393-402. doi: 10.1016/S0140-6736(10)60959-2. Epub 2010 Aug 23. Erratum in: Lancet. 2011 Jan 29;377(9763):382.

PMID:
20739054
5.

Distinguishing myelodysplastic syndromes (MDS) from idiopathic cytopenia of undetermined significance (ICUS): HUMARA unravels clonality in a subgroup of patients.

Schroeder T, Ruf L, Bernhardt A, Hildebrandt B, Aivado M, Aul C, Gattermann N, Haas R, Germing U.

Ann Oncol. 2010 Nov;21(11):2267-71. doi: 10.1093/annonc/mdq233. Epub 2010 May 3.

PMID:
20439346
6.

Reduced proliferation of non-megakaryocytic acute myelogenous leukemia and other leukemia and lymphoma cell lines in response to eltrombopag.

Erickson-Miller CL, Kirchner J, Aivado M, May R, Payne P, Chadderton A.

Leuk Res. 2010 Sep;34(9):1224-31. doi: 10.1016/j.leukres.2010.02.005. Epub 2010 Mar 3.

PMID:
20202683
7.

Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome.

Will B, Kawahara M, Luciano JP, Bruns I, Parekh S, Erickson-Miller CL, Aivado MA, Verma A, Steidl U.

Blood. 2009 Oct 29;114(18):3899-908. doi: 10.1182/blood-2009-04-219493. Epub 2009 Aug 26.

8.

Comparative analyses of the small molecule thrombopoietin receptor agonist eltrombopag and thrombopoietin on in vitro platelet function.

Erhardt JA, Erickson-Miller CL, Aivado M, Abboud M, Pillarisetti K, Toomey JR.

Exp Hematol. 2009 Sep;37(9):1030-7. doi: 10.1016/j.exphem.2009.06.011. Epub 2009 Jul 24.

PMID:
19631713
9.

Platelet counts and haemorrhagic diathesis in patients with myelodysplastic syndromes.

Neukirchen J, Blum S, Kuendgen A, Strupp C, Aivado M, Haas R, Aul C, Gattermann N, Germing U.

Eur J Haematol. 2009 Nov;83(5):477-82. doi: 10.1111/j.1600-0609.2009.01299.x. Epub 2009 Jun 22.

PMID:
19548919
10.

Meningioma 1 gene is differentially expressed in CD34 positive cells from bone marrow of patients with myelodysplastic syndromes with the highest expression in refractory anemia with excess of blasts and secondary acute myeloid leukemia.

Schroeder T, Czibere A, Zohren F, Aivado M, Gattermann N, Germing U, Haas R.

Leuk Lymphoma. 2009 Jun;50(6):1043-6. doi: 10.1080/10428190902913591. No abstract available.

PMID:
19391034
11.

Differential gene expression of bone marrow-derived CD34+ cells is associated with survival of patients suffering from myelodysplastic syndrome.

Prall WC, Czibere A, Grall F, Spentzos D, Steidl U, Giagounidis AAN, Kuendgen A, Otu H, Rong A, Libermann TA, Germing U, Gattermann N, Haas R, Aivado M.

Int J Hematol. 2009 Mar;89(2):173-187. doi: 10.1007/s12185-008-0242-9. Epub 2009 Jan 20.

PMID:
19152102
12.

Proteomic identification of interleukin-2 therapy response in metastatic renal cell cancer.

Jones J, Otu HH, Grall F, Spentzos D, Can H, Aivado M, Belldegrun AS, Pantuck AJ, Libermann TA.

J Urol. 2008 Feb;179(2):730-6. Epub 2007 Dec 20.

13.

Age-related transcription levels of KU70, MGST1 and BIK in CD34+ hematopoietic stem and progenitor cells.

Prall WC, Czibere A, Jäger M, Spentzos D, Libermann TA, Gattermann N, Haas R, Aivado M.

Mech Ageing Dev. 2007 Sep;128(9):503-10. Epub 2007 Jul 4.

PMID:
17714764
14.

Analysis and robot pipelined automation for SELDI-TOF mass spectrometry.

Alterovitz G, Aivado M, Spentzos D, Libermann TA, Ramoni M, Kohane IS.

Conf Proc IEEE Eng Med Biol Soc. 2004;4:3068-71.

PMID:
17270926
15.

Serum proteome profiling detects myelodysplastic syndromes and identifies CXC chemokine ligands 4 and 7 as markers for advanced disease.

Aivado M, Spentzos D, Germing U, Alterovitz G, Meng XY, Grall F, Giagounidis AA, Klement G, Steidl U, Otu HH, Czibere A, Prall WC, Iking-Konert C, Shayne M, Ramoni MF, Gattermann N, Haas R, Mitsiades CS, Fung ET, Libermann TA.

Proc Natl Acad Sci U S A. 2007 Jan 23;104(4):1307-12. Epub 2007 Jan 12.

16.

Perspectives of proteomics in acute myeloid leukemia.

Czibere A, Grall F, Aivado M.

Expert Rev Anticancer Ther. 2006 Nov;6(11):1663-75. Review.

PMID:
17134369
17.

Myelodysplastic syndromes in patients younger than age 50.

Kuendgen A, Strupp C, Aivado M, Hildebrandt B, Haas R, Gattermann N, Germing U.

J Clin Oncol. 2006 Dec 1;24(34):5358-65. Epub 2006 Nov 6.

PMID:
17088566
18.

Essential role of Jun family transcription factors in PU.1 knockdown-induced leukemic stem cells.

Steidl U, Rosenbauer F, Verhaak RG, Gu X, Ebralidze A, Otu HH, Klippel S, Steidl C, Bruns I, Costa DB, Wagner K, Aivado M, Kobbe G, Valk PJ, Passegué E, Libermann TA, Delwel R, Tenen DG.

Nat Genet. 2006 Nov;38(11):1269-77. Epub 2006 Oct 15.

PMID:
17041602
19.

Exisulind induces apoptosis in advanced myelodysplastic syndrome (MDS) and acute myeloid leukaemia/MDS.

Czibere A, Prall WC, Zerbini LF, Jäger M, Kobbe G, Knipp S, Libermann TA, Haas R, Aivado M.

Br J Haematol. 2006 Nov;135(3):355-7. Epub 2006 Sep 15.

PMID:
16978222
20.

Urine proteomic profiling of pediatric nephrotic syndrome.

Khurana M, Traum AZ, Aivado M, Wells MP, Guerrero M, Grall F, Libermann TA, Schachter AD.

Pediatr Nephrol. 2006 Sep;21(9):1257-65. Epub 2006 Jun 30.

21.

X-linked sideroblastic anemia associated with a novel ALAS2 mutation and unfortunate skewed X-chromosome inactivation patterns.

Aivado M, Gattermann N, Rong A, Giagounidis AA, Prall WC, Czibere A, Hildebrandt B, Haas R, Bottomley SS.

Blood Cells Mol Dis. 2006 Jul-Aug;37(1):40-5. Epub 2006 Jun 2.

PMID:
16735131
22.

Rituximab long-term maintenance therapy after autologous stem cell transplantation in patients with B-cell non-Hodgkin's lymphoma.

Neumann F, Harmsen S, Martin S, Kronenwett R, Kondakci M, Aivado M, Germing U, Haas R, Kobbe G.

Ann Hematol. 2006 Aug;85(8):530-4. Epub 2006 Apr 26.

PMID:
16639571
23.

SELDI-TOF MS of quadruplicate urine and serum samples to evaluate changes related to storage conditions.

Traum AZ, Wells MP, Aivado M, Libermann TA, Ramoni MF, Schachter AD.

Proteomics. 2006 Mar;6(5):1676-80.

24.

Refractory anaemia with excess of blasts (RAEB): analysis of reclassification according to the WHO proposals.

Germing U, Strupp C, Kuendgen A, Aivado M, Giagounidis A, Hildebrandt B, Aul C, Haas R, Gattermann N.

Br J Haematol. 2006 Jan;132(2):162-7. Erratum in: Br J Haematol. 2006 Jul;134(2):247.

PMID:
16398650
25.

The ratio between CD4+ and CD8+ cells in the peripheral blood of patients with hematological malignancies is not altered by thalidomide.

Strupp C, Germing U, Aivado M, Kündgen A, Fenk R, Hünerlitürkoglu A, Kobbe G, Haas R, Gattermann N.

Leuk Lymphoma. 2005 Jul;46(7):999-1006.

PMID:
16019550
26.

Difference in clinical features between Japanese and German patients with refractory anemia in myelodysplastic syndromes.

Matsuda A, Germing U, Jinnai I, Misumi M, Kuendgen A, Knipp S, Aivado M, Iwanaga M, Miyazaki Y, Tsushima H, Sakai M, Bessho M, Tomonaga M.

Blood. 2005 Oct 15;106(8):2633-40. Epub 2005 Jun 21.

27.

The nonsteroidal anti-inflammatory drug Exisulind selectively induces apoptosis via JNK in secondary acute myeloid leukemia after myelodysplastic syndrome.

Czibere A, Prall WC, Zerbini LF, Grall F, Craigie EC, Ulrich SD, Giagounidis AA, Haas R, Libermann TA, Aivado M.

Cell Cycle. 2005 Jun;4(6):812-7. Epub 2005 Jun 8.

PMID:
15970671
28.

Optimization and evaluation of surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) with reversed-phase protein arrays for protein profiling.

Aivado M, Spentzos D, Alterovitz G, Otu HH, Grall F, Giagounidis AA, Wells M, Cho JY, Germing U, Czibere A, Prall WC, Porter C, Ramoni MF, Libermann TA.

Clin Chem Lab Med. 2005;43(2):133-40.

PMID:
15843205
29.

Treatment of myelodysplastic syndrome with isolated del(5q) including bands q31-q33 with a combination of all-trans-retinoic acid and tocopherol-alpha: a phase II study.

Giagounidis AA, Haase S, Germing U, Schlegelberger B, Wilkens L, Büsche G, Kreipe HH, Wysk J, Grips KH, Grabenhorst U, Rothmann F, Lübbert M, Ganser A, Aivado M, Heinsch M, Aul C.

Ann Hematol. 2005 Jun;84(6):389-94. Epub 2005 Mar 23.

PMID:
15785949
30.

Transplantation of allogeneic CD34+-selected cells followed by early T-cell add-backs: favorable results in acute and chronic myeloid leukemia.

Kobbe G, Fenk R, Neumann F, Bernhardt A, Steidl U, Kondakci M, Graef T, Aivado M, Vaupel M, Huenerlituerkoglu AN, Kronenwett R, Pape H, Hildebrand B, Germing U, Haas R.

Cytotherapy. 2004;6(6):533-42.

PMID:
15764020
31.

Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid.

Kuendgen A, Strupp C, Aivado M, Bernhardt A, Hildebrandt B, Haas R, Germing U, Gattermann N.

Blood. 2004 Sep 1;104(5):1266-9. Epub 2004 May 20.

32.

Primary human CD34+ hematopoietic stem and progenitor cells express functionally active receptors of neuromediators.

Steidl U, Bork S, Schaub S, Selbach O, Seres J, Aivado M, Schroeder T, Rohr UP, Fenk R, Kliszewski S, Maercker C, Neubert P, Bornstein SR, Haas HL, Kobbe G, Tenen DG, Haas R, Kronenwett R.

Blood. 2004 Jul 1;104(1):81-8. Epub 2004 Mar 11.

33.

Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31.

Giagounidis AA, Germing U, Haase S, Hildebrandt B, Schlegelberger B, Schoch C, Wilkens L, Heinsch M, Willems H, Aivado M, Aul C.

Leukemia. 2004 Jan;18(1):113-9.

PMID:
14586479
34.

Quantitative real-time reverse-transcription polymerase chain reaction for diagnosis of BCR-ABL positive leukemias and molecular monitoring following allogeneic stem cell transplantation.

Neumann F, Herold C, Hildebrandt B, Kobbe G, Aivado M, Rong A, Free M, Rössig R, Fenk R, Schneider P, Gattermann N, Royer-Pokora B, Haas R, Kronenwett R.

Eur J Haematol. 2003 Jan;70(1):1-10.

PMID:
12631253
35.

The emergence of a C/EBPalpha mutation in the clonal evolution of MDS towards secondary AML.

Kaeferstein A, Krug U, Tiesmeier J, Aivado M, Faulhaber M, Stadler M, Krauter J, Germing U, Hofmann WK, Koeffler HP, Ganser A, Verbeek W.

Leukemia. 2003 Feb;17(2):343-9.

PMID:
12592334
36.

Treatment of secondary myelodysplastic syndrome after heart transplantation with chemotherapy and nonmyeloablative stem-cell transplantation.

Kobbe G, Germing U, Aivado M, Zohren F, Schubert D, Strupp C, Pape H, Tenderich G, Körfer R, Storb R, Haas R, Schneider P.

Transplantation. 2002 Oct 27;74(8):1198-200.

PMID:
12438973
37.

Reliable engraftment, low toxicity, and durable remissions following allogeneic blood stem cell transplantation with minimal conditioning.

Kobbe G, Schneider P, Aivado M, Zohren F, Schubert D, Fenk R, Neumann F, Kronenwett R, Pape H, Rong A, Royer-Pokora B, Hildebrandt B, Germing U, Gattermann N, Heyll A, Haas R.

Exp Hematol. 2002 Nov;30(11):1346-53.

PMID:
12423689
38.

Bendamustine in the treatment of chronic lymphocytic leukemia: results and future perspectives.

Aivado M, Schulte K, Henze L, Burger J, Finke J, Haas R.

Semin Oncol. 2002 Aug;29(4 Suppl 13):19-22.

PMID:
12170428
39.

New prognostic parameters for chronic myelomonocytic leukemia.

Germing U, Strupp C, Aivado M, Gattermann N.

Blood. 2002 Jul 15;100(2):731-2; author reply 732-3. No abstract available.

40.

Favourable response to antithymocyte or antilymphocyte globulin in low-risk myelodysplastic syndrome patients with a 'non-clonal' pattern of X-chromosome inactivation in bone marrow cells.

Aivado M, Rong A, Stadler M, Germing U, Giagounidis A, Strupp C, Novotny J, Josten KM, Kobbe G, Hildebrandt B, Gattermann N, Aul C, Haas R, Ganser A.

Eur J Haematol. 2002 Apr;68(4):210-6.

PMID:
12071936
41.

Angioimmunoblastic lymphadenopathy (AILD) may respond to thalidomide treatment: two case reports.

Strupp C, Aivado M, Germing U, Gattermann N, Haas R.

Leuk Lymphoma. 2002 Jan;43(1):133-7.

PMID:
11908717
42.

Testicular infiltration in acute myeloid leukemia with complex karyotype including t(8;21).

Giagounidis AA, Hildebrandt B, Braunstein S, Aivado M, Germing U, Heinsch M, Aul C.

Ann Hematol. 2002 Feb;81(2):115-8. Epub 2001 Dec 8.

PMID:
11907795
43.

Gene expression profiling identifies significant differences between the molecular phenotypes of bone marrow-derived and circulating human CD34+ hematopoietic stem cells.

Steidl U, Kronenwett R, Rohr UP, Fenk R, Kliszewski S, Maercker C, Neubert P, Aivado M, Koch J, Modlich O, Bojar H, Gattermann N, Haas R.

Blood. 2002 Mar 15;99(6):2037-44.

44.

Thalidomide for the treatment of patients with myelodysplastic syndromes.

Strupp C, Germing U, Aivado M, Misgeld E, Haas R, Gattermann N.

Leukemia. 2002 Jan;16(1):1-6.

45.

Acute basophilic leukemia.

Giagounidis AA, Hildebrandt B, Heinsch M, Germing U, Aivado M, Aul C.

Eur J Haematol. 2001 Aug;67(2):72-6.

PMID:
11722593
46.

Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse antiTNFalpha antibody.

Kobbe G, Schneider P, Rohr U, Fenk R, Neumann F, Aivado M, Dietze L, Kronenwett R, Hünerlitürkoglu A, Haas R.

Bone Marrow Transplant. 2001 Jul;28(1):47-9.

47.

X chromosome inactivation ratios in female carriers of X-linked sideroblastic anemia.

Aivado M, Gattermann N, Bottomley S.

Blood. 2001 Jun 15;97(12):4000-2. No abstract available.

48.

["Field cancerization"--an additional phenomenon in development of colon tumors? K-ras codon 12 mutations in normal colonic mucosa of patients with colorectal neoplasms].

Aivado M, Gynes M, Gorelov V, Schmidt WU, Röher HD, Goretzki PE.

Chirurg. 2000 Oct;71(10):1230-4; discussion 1234-5. German.

PMID:
11077584
49.
50.

Long-term remission after intensive chemotherapy in advanced myelodysplastic syndromes is generally associated with restoration of polyclonal haemopoiesis.

Aivado M, Rong A, Germing U, Gattermann N, Kobbe G, Rieth C, Haas R, Aul C.

Br J Haematol. 2000 Sep;110(4):884-6.

PMID:
11054075

Supplemental Content

Loading ...
Support Center